Combined Administration of Plasmids Encoding IL-4 and IL-10 Prevents the Development of Autoimmune Diabetes in Nonobese Diabetic Mice
Open Access
- 1 October 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 4 (4), 313-316
- https://doi.org/10.1006/mthe.2001.0459
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD miceGene Therapy, 2000
- Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transferGene Therapy, 2000
- Systemic Delivery of Interleukin 10 by Intramuscular Injection of Expression Plasmid DNA Prevents Autoimmune Diabetes in Nonobese Diabetic MiceHuman Gene Therapy, 1998
- Pharmacokinetic considerations in somatic gene therapyAdvanced Drug Delivery Reviews, 1998
- PRIMARY NONFUNCTION OF ISLET GRAFTS IN AUTOIMMUNE DIABETIC NONOBESE DIABETIC MICE IS PREVENTED BY TREATMENT WITH INTERLEUKIN-4 AND INTERLEUKIN-101Transplantation, 1996
- Recombinant Human IL-10 Prevents the Onset of Diabetes in the Nonobese Diabetic MouseClinical Immunology and Immunopathology, 1994
- Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivoEuropean Journal of Immunology, 1993
- Interleukin‐4 and interleukin‐10 inhibit nitric oxide‐dependent macrophage killing of Candida albicansEuropean Journal of Immunology, 1993
- Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.The Journal of Experimental Medicine, 1993
- Macrophage deactivation by interleukin 10.The Journal of Experimental Medicine, 1991